BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Banham G, Prezzi D, Harford S, Taylor CJ, Hamer R, Higgins R, Bradley JA, Clatworthy MR. Elevated pretransplantation soluble BAFF is associated with an increased risk of acute antibody-mediated rejection. Transplantation. 2013;96:413-420. [PMID: 23842189 DOI: 10.1097/tp.0b013e318298dd65] [Cited by in Crossref: 50] [Cited by in F6Publishing: 21] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Nouël A, Simon Q, Jamin C, Pers JO, Hillion S. Regulatory B cells: an exciting target for future therapeutics in transplantation. Front Immunol 2014;5:11. [PMID: 24478776 DOI: 10.3389/fimmu.2014.00011] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
2 Xu H, Samy KP, Guasch A, Mead SI, Ghali A, Mehta A, Stempora L, Kirk AD. Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients. Am J Transplant 2016;16:550-64. [PMID: 26436448 DOI: 10.1111/ajt.13469] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
3 Engels EA, Jennings LW, Everly MJ, Landgren O, Murata K, Yanik EL, Pfeiffer RM, Onaca N, Klintmalm GB. Donor-specific Antibodies, Immunoglobulin-free Light Chains, and BAFF Levels in Relation to Risk of Late-onset PTLD in Liver Recipients. Transplant Direct 2018;4:e353. [PMID: 30123826 DOI: 10.1097/TXD.0000000000000792] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
4 Karahan GE, Claas FH, Heidt S. B Cell Immunity in Solid Organ Transplantation. Front Immunol 2016;7:686. [PMID: 28119695 DOI: 10.3389/fimmu.2016.00686] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
5 Salvadori M, Bertoni E. Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy. World J Transplant 2014; 4(1): 1-17 [PMID: 24669363 DOI: 10.5500/wjt.v4.i1.1] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wang XZ, Wan Z, Xue WJ, Zheng J, Li Y, Ding CG. B-Cell Activating Factor Predicts Acute Rejection Risk in Kidney Transplant Recipients: A 6-Month Follow-Up Study. Front Immunol 2019;10:1046. [PMID: 31156628 DOI: 10.3389/fimmu.2019.01046] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
7 Irure-Ventura J, San Segundo D, Rodrigo E, Merino D, Belmar-Vega L, Ruiz San Millán JC, Valero R, Benito A, López-Hoyos M. High Pretransplant BAFF Levels and B-cell Subset Polarized towards a Memory Phenotype as Predictive Biomarkers for Antibody-Mediated Rejection. Int J Mol Sci 2020;21:E779. [PMID: 31991734 DOI: 10.3390/ijms21030779] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
8 Gorbacheva V, Ayasoufi K, Fan R, Baldwin WM 3rd, Valujskikh A. B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) mediate CD40-independent help by memory CD4 T cells. Am J Transplant 2015;15:346-57. [PMID: 25496308 DOI: 10.1111/ajt.12984] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
9 Shi J, Xu X, Luo F, Shi Q, He X, Xia Y. Differences in Tfh Cell Response Between the Graft and Spleen With Chronic Allograft Nephropathy. Cell Transplant 2017;26:95-102. [PMID: 27524795 DOI: 10.3727/096368916X692816] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Townamchai N, Eiam-Ong S. Biomarkers in kidney transplantation: From bench to bedside. World J Nephrol 2015; 4(5): 487-491 [PMID: 26558185 DOI: 10.5527/wjn.v4.i5.487] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
11 Higgins RM, Daga S, Mitchell DA. Antibody-incompatible kidney transplantation in 2015 and beyond. Nephrol Dial Transplant 2015;30:1972-8. [PMID: 25500804 DOI: 10.1093/ndt/gfu375] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
12 Steines L, Poth H, Schuster A, Amann K, Banas B, Bergler T. Disruption of Tfh:B Cell Interactions Prevents Antibody-Mediated Rejection in a Kidney Transplant Model in Rats: Impact of Calcineurin Inhibitor Dose. Front Immunol 2021;12:657894. [PMID: 34135891 DOI: 10.3389/fimmu.2021.657894] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kwun J, Page E, Hong JJ, Gibby A, Yoon J, Farris AB, Villinger F, Knechtle S. Neutralizing BAFF/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model. Am J Transplant 2015;15:815-22. [PMID: 25675879 DOI: 10.1111/ajt.13045] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 6.1] [Reference Citation Analysis]
14 Afzali S, Salehi S, Shahi A, Esmaeili M, Farashi Bonab S, Peykari A, Bagherpour F, Ansaripour B, Soleimanian T, Pour-Reza-Gholi F, Amirzargar A. Investigating the Role of BAFF and Its Receptors in Renal Transplant Recipients with Chronic Antibody-Mediated Rejection. J Immunol Res 2021;2021:6654992. [PMID: 33748289 DOI: 10.1155/2021/6654992] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Doshi BS, Rana J, Castaman G, Shaheen MA, Kaczmarek R, Butterfield JS, Meeks SL, Leissinger C, Biswas M, Arruda VR. B cell-activating factor modulates the factor VIII immune response in hemophilia A. J Clin Invest 2021;131:142906. [PMID: 33651716 DOI: 10.1172/JCI142906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Clatworthy MR. B cell modulation in transplantation. Clin Exp Immunol 2014;178 Suppl 1:61-3. [PMID: 25546764 DOI: 10.1111/cei.12513] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
17 Valenzuela NM, Reed EF. Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies. J Clin Invest 2017;127:2492-504. [PMID: 28604384 DOI: 10.1172/JCI90597] [Cited by in Crossref: 83] [Cited by in F6Publishing: 36] [Article Influence: 16.6] [Reference Citation Analysis]
18 Cohney S, Masterson R, Hogan C, Hughes P, Haeusler M. ABOi with conventional immunosuppression alone-antiblood group antibody isn't the only contributor to antibody-mediated rejection and/or thrombotic microangiopathy. Am J Transplant 2015;15:1730-2. [PMID: 25912527 DOI: 10.1111/ajt.13256] [Reference Citation Analysis]
19 Olaso D, Manook M, Moris D, Knechtle S, Kwun J. Optimal Immunosuppression Strategy in the Sensitized Kidney Transplant Recipient. J Clin Med 2021;10:3656. [PMID: 34441950 DOI: 10.3390/jcm10163656] [Reference Citation Analysis]
20 Xu H, He X, Xu R. B Cell Activating Factor, Renal Allograft Antibody-Mediated Rejection, and Long-Term Outcome. J Immunol Res 2018;2018:5251801. [PMID: 29977928 DOI: 10.1155/2018/5251801] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
21 Min JW, Shin YJ, Lee H, Kim BM, Park KH, Doh KC, Kim TM, Lim SW, Yang CW, Oh EJ, Chung BH. BAFF Inhibition Effectively Suppresses the Development of Anti-HLA.A2 Antibody in the Highly Sensitized Mouse Model. Int J Mol Sci 2021;22:E861. [PMID: 33467096 DOI: 10.3390/ijms22020861] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Min JW, Kim KW, Kim BM, Doh KC, Choi MS, Choi BS, Park CW, Yang CW, Kim YS, Oh EJ, Chung BH. Clinical Significance of Pre- and Post-Transplant BAFF Levels in Kidney Transplant Recipients. PLoS One 2016;11:e0162964. [PMID: 27631619 DOI: 10.1371/journal.pone.0162964] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]